Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care
Retatrutide is back in the spotlight. Eli Lilly is gearing up to drop fresh clinical data on retatrutide at the American Diabetes Association’s 86th Scientific Sessions. Alongside Mounjaro and the newly named Foundayo, retatrutide is shaping up as a major player in the next wave of research peptides for diabetes and obesity.
PR Newswire
“Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care PR Newswire”
Here’s why this matters for anyone keeping tabs on peptide science:
Retatrutide is a multi-action peptide. It targets GLP-1, GIP, and glucagon receptors—triple agonism. That’s a big deal for researchers focused on metabolic regulation.
The new data will likely showcase both efficacy and safety across diverse populations. More details mean more angles for researchers to explore.
Lilly is signaling serious intent. They’re not just presenting one compound—they’re putting the whole bench on display. This isn’t just about clinical trials; it’s about setting the tone for what’s coming next in metabolic research.
What to watch for as the sessions kick off:
Comparative results: With Mounjaro and Foundayo in the mix, researchers get a rare side-by-side look at new and established peptide candidates.
Mechanistic insights: Expect deeper dives on how retatrutide interacts with its targets and what that means for designing next-gen research protocols.
New questions: More data often means new research opportunities—think combination studies, dose optimization, or even novel delivery routes.
Key takeaway: Retatrutide is moving fast, and the research community is watching closely. For those interested in sourcing or further study, the retatrutide page has background and links. For sourcing, check out the vendor directory.
Stay tuned—retatrutide isn’t just another peptide on the list. It’s one of the most interesting compounds in metabolic research today.
Related Reading
Saitama University researchers discover that a natural peptide aptamer switches between two target proteins depending on metal ions
News · EIN PresswirePeptide Therapeutics Market Revenue To Cross $222 Billion By 2030 Supported By Rising Demand
News · The Globe and MailPepMD Launches to Establish Credentialing and Trust Standards for Peptide Medicine
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.